What happened
RPbio reported separate results for FY2025: revenue of US$94.5M (+9.9% year on year), operating profit of US$3.61M (from a loss a year earlier) and net income of US$2.91M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$94.5M |
|---|---|
| Revenue vs a year earlier | +9.9% |
| Operating profit | US$3.61M |
| Net income | US$2.91M |
| Period | FY2025 (separate) |
| Filed | 2026-02-13, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260213901525 → open original filing |
Source: DART. Information only, not investment advice.